Antidiabetic substituted heteroaryl compounds

US9834563B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• William K. Hagmann · Westfield, US
• Bing Li · Towaco, US
• Jason W. Szewczyk · Collegeville, US
• Bowei Wang · Westfield, US
• Dann Parker · Cranford, US
• Timothy A. Blizzard · Middletown, US
• Hubert Josien · Hoboken, US
• Purakkattle Biju · Piscataway, US
• Harry R. Chobanian · Kenilworth, US
• Candido Gude · Staten Island, US
• Ravi Nargund · East Brunswick Township, US
• Barbara Pio · West Orange, US
• Qun Dang · Westfield, US
• Linus S. Lin · Westfield, US
• Bin Hu · Mesa, US
• Mingxiang Cui · Shanghai, CN
• Zhengxia Chen · Shanghai, CN
• Meibi Dai · Shanghai, CN
• Zaihong Zhang · Shanghai, CN
• Ying Lv · Shanghai, CN
• Lili Tian · Shanghai, CN

Key dates

• Filing date: Dec 17, 2014
• Grant date: Dec 5, 2017
• Expiry date: Dec 17, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.